Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis
Error in calculating costs of screening: In “Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis” in the 3 June 2013 issue of the Journal (Med J Aust 2013; 198: 546-550), there was an error in the way screening costs were calculated. These corrections do not alter the study conclusions. The corrected figures are in bold as follows.
Results section of the abstract (page 546): “The base-case incremental cost effectiveness ratio of PSA screening was $168 611 per QALY for men with average risk, $73 452 per QALY for men with two times the average risk, and $22 938 per QALY for men with five times the average risk.”
First paragraph of the results section (page 547): “For men with an average risk, PSA screening led to an additional 2.7 quality-adjusted life-days (14.3 undiscounted) at an additional cost of $1263, giving an incremental cost effectiveness ratio (ICER) of $168 611 per…